Search - tctmd.com

Displaying 121 - 140 of 2580

Sort: Relevancy | Date

Presentation TCT 2016

Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory!

Presenter: Raj Makkar, Lars Sondergaard, Haim Danenberg

October 31, 2016

Presentation TCT 2016

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

Presenter: Raj Makkar, Lars Sondergaard, Axel Linke

October 31, 2016

Presentation TCT 2016

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Presenter: Raj Makkar, Lars Sondergaard, Samir R. Kapadia

October 31, 2016

TCT 80: Transradial Diagnostic and Therapeutic Coronary Catheterization for Patients With NSTEMI or UAP Using One 4.0-Fr Sheath and One Sheathless Eaucathe Guide Catheter via One Puncture Site: 1-1-1 Trial

Presentation TCT 2016

TCT 80: Characterizing the Incidence and Predictors of Paravalvular Regurgitation after Transcatheter Aortic Valve Replacement (TAVR) and its Impact on Outcomes: A Study of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valv

Presenter: John M. Lasala, Philippe Pibarot, Saif Anwaruddin

October 31, 2016

Presentation TCT 2016

TCT 83: Transcatheter Aortic Valve Replacement With Different Valve Designs for Elliptic Aortic Annulus Shape

Presenter: Mayra Guerrero, Roger J. Laham, Yoshio Maeno

October 31, 2016

Presentation TCT 2016

TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation

Presenter: John M. Lasala, Philippe Pibarot, Jürgen Rothe

October 31, 2016

Presentation TCT 2016

TCT 82: Evaluation of Current Practices in Transcatheter Aortic Valve Replacement: The WRITTEN (Worldwide TAVR Experience)Survey

Presenter: Mayra Guerrero, Roger J. Laham, Luis Nombela-Franco

October 31, 2016

Presentation TCT 2016

TCT 78: Incidence and Outcomes of Vascular Complications and Bleeding Events in Patients Undergoing TAVR in Contemporary U.S. Practice: Insights From the STS/ACC TVT Registry®

Presenter: John M. Lasala, Philippe Pibarot, Matthew Sherwood

October 31, 2016

Presentation TCT 2016

TCT 81: Clinical and Hemodynamic Results After Direct Transcatheter Aortic Valve Replacement Versus Pre-Implantation Balloon Aortic Valvuloplasty. A Case-Matched Analysis

Presenter: Mayra Guerrero, Roger J. Laham, Luis Nombela-Franco

October 31, 2016

Presentation TCT 2016

TCT 77: Association of Residual Mitral Regurgitation After Transcatheter Aortic Valve Replacement With Readmission for Acute Heart Failure: An Analysis From PARTNER 1

Presenter: John M. Lasala, Philippe Pibarot, John Petersen

October 31, 2016

Presentation TCT 2016

TCT 40: One-Year Outcome of a Multicenter Clinical Study Evaluating a Novel Self-Expanding and Resheathable Transcatheter Aortic Valve System

Presenter: Lutz Buellesfeld, Raj Makkar, Ganesh Manoharan

October 31, 2016

Presentation TCT 2016

TCT 36: Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Philip Green

October 31, 2016

Presentation TCT 2016

TCT 39: Three-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II CE-Mark Study

Presenter: Lutz Buellesfeld, Raj Makkar, Ian T. Meredith

October 31, 2016

Presentation TCT 2016

TCT 35: Predictors of Early Aortic Valve Rehospitalization Following Self-Expanding Transcatheter Aortic Valve Replacement: Results From the CoreValve US Trial Program

Presenter: Charles J. Davidson, Michael J. Reardon, James B. Hermiller Jr.

October 31, 2016

Presentation TCT 2016

Rationale for and Design of TAVR UNLOAD: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Michael Argenziano, Alec S. Vahanian, Daniel Burkhoff

October 31, 2016

Presentation TCT 2016

TCT 38: Paravalvular Regurgitation Regression and Impact on One-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Transcatheter Valve

Presenter: Lutz Buellesfeld, Raj Makkar, Philippe Pibarot

October 31, 2016

Title Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presentation TCT 2016

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Suzanne Baron

October 31, 2016

Presentation TCT 2016

TCT 37: Transcatheter Aortic Valve Replacement With a Repositionable Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at High Risk for Surgery: One-Year Results From the Evolut R US Pivotal Study

Presenter: Lutz Buellesfeld, Raj Makkar, Jeffrey J. Popma

October 31, 2016

Presentation TCT 2016

TCT 33: Predictors of Hospital Readmissions After Transcatheter Aortic Valve Replacement

Presenter: Charles J. Davidson, Michael J. Reardon, James Harvey

October 31, 2016

Presentation TCT 2016

Editorial Perspective: Embolic Protection in TAVR Intervention

Presenter: Josep Rodés-Cabau

October 31, 2016

Advertisement

Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory!

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

TCT 80: Characterizing the Incidence and Predictors of Paravalvular Regurgitation after Transcatheter Aortic Valve Replacement (TAVR) and its Impact on Outcomes: A Study of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valv

TCT 83: Transcatheter Aortic Valve Replacement With Different Valve Designs for Elliptic Aortic Annulus Shape

TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation

TCT 82: Evaluation of Current Practices in Transcatheter Aortic Valve Replacement: The WRITTEN (Worldwide TAVR Experience)Survey

TCT 78: Incidence and Outcomes of Vascular Complications and Bleeding Events in Patients Undergoing TAVR in Contemporary U.S. Practice: Insights From the STS/ACC TVT Registry®

TCT 81: Clinical and Hemodynamic Results After Direct Transcatheter Aortic Valve Replacement Versus Pre-Implantation Balloon Aortic Valvuloplasty. A Case-Matched Analysis

TCT 77: Association of Residual Mitral Regurgitation After Transcatheter Aortic Valve Replacement With Readmission for Acute Heart Failure: An Analysis From PARTNER 1

TCT 40: One-Year Outcome of a Multicenter Clinical Study Evaluating a Novel Self-Expanding and Resheathable Transcatheter Aortic Valve System

TCT 36: Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial

TCT 39: Three-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II CE-Mark Study

TCT 35: Predictors of Early Aortic Valve Rehospitalization Following Self-Expanding Transcatheter Aortic Valve Replacement: Results From the CoreValve US Trial Program

Rationale for and Design of TAVR UNLOAD: What I Expect the Findings to Be But What Wont Surprise Me!

TCT 38: Paravalvular Regurgitation Regression and Impact on One-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Transcatheter Valve

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

TCT 37: Transcatheter Aortic Valve Replacement With a Repositionable Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at High Risk for Surgery: One-Year Results From the Evolut R US Pivotal Study

TCT 33: Predictors of Hospital Readmissions After Transcatheter Aortic Valve Replacement

Editorial Perspective: Embolic Protection in TAVR Intervention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content